ORLANDO, Fla., April 16, 2010 (GLOBE NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., has issued a research update on Aethlon Medical, Inc. (OTCBB:AEMD), a company developing a therapeutic device to treat acute and chronic viral infections, biological warfare pathogens, and other conditions by filtering virus particles and immunosuppressive agents from the blood.
David Webber, RedChip Research Analyst, reported:
"During the early months of 2010, Aethlon advanced its core Hepatitis C program with manufacturing progress and steps towards early commercialization in India and helped lay the groundwork for studies in exosomes, which could lead to use in the treatment of certain types of cancer."
"Aethlon has moved to a strategy that focuses on early commercialization in India, where the market would be a mix of medical tourists and Indian citizens. As we believe that the Company at this point could not afford to do the sort of clinical trials needed for U.S. or EU approvals, the Indian strategy appears to make sense as a means to increase real-world experience with the Hemopurifier in HCV therapy while offsetting expenses with sales revenues."
"In our opinion, commercialization in India would increase the clinical database and, assuming positive patient outcomes, improve the odds for a development and marketing partnership, a likely necessity for eventual commercialization in the United States and/or Europe. The probability of these steps has increased in recent months through a favorable classification of the Hemopurifier by the Indian authorities and work to develop treatment protocols for HCV patients in India."
"In addition, the Company completed a successful pilot production run under Good Manufacturing Practices (GMP) standards, a Food & Drug Administration (FDA) requirement for device export, and reached a tentative commercial manufacturing contract with Membrana GmbH, a global leader in hollow fiber filter technology and production."
Webber continued, "We rate Aethlon Medical a Speculative Buy with a 12-month price target of $1.00 per share. We expect the chief driver of the stock over the next year to be steps towards commercialization for the treatment in India."
To receive a complimentary copy of the RedChip Visibility Research Update for AEMD, please visit: http://www.redchip.com/about/aboutmain.asp?rid=230">http://www.redchip.com/about/aboutmain.asp?rid=230
To learn more about Aethlon, visit http://www.redchip.com/visibility/investor.asp?symbol=AEMD.
About Aethlon Medical
Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our lead product, the Hemopurifier®, is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection. Human studies have documented the ability of our Hemopurifier® to reduce viral load in patients infected with the Hepatitis C Virus (HCV) and the Human Immunodeficiency Virus (HIV). Our primary clinical and commercialization focus is to establish the Hemopurifier® as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.
The Hemopurifier® is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
Exosome Sciences, Inc. (ESI) was formed in October of 2009 to leverage attributes of the Hemopurifier® in the emerging exosome research field. ESI seeks to inhibit the immune cell destruction caused by exosomes secreted by solid tumors, lymphomas, and leukemia. At present, the capture of immunosuppressive exosomes secreted from ovarian cancer tumors has been demonstrated invitro. The preservation of anti-cancer immune cells would likely improve patient responsiveness to established treatment options, including immunotherapy and chemotherapy. ESI is also analyzing exosome-related opportunities to improve early cancer detection and post-surgery surveillance of tumor growth, as well as approaches to harvest exosomes for research purposes and potential reintroduction into patients afflicted with autoimmune conditions such as Rheumatoid Arthritis and Lupus.
Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at http://www.aethlonmedical.com/.
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida with affiliate offices in Qingdao, China; Paris and San Diego. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV™, Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio™. To learn more about RedChip's products and services .please visit: http://www.redchip.com/visibility/productsandservices.asp.
"Discovering Tomorrow's Blue Chips Today"™
The RedChip Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2761
Disclosure
The analysts contributing to this report do not hold any shares of Aethlon Medical, Inc. (AEMD). RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. The equity research report(s) are not a recommendation of a solicitation to purchase or sell any security, nor do they constitute investment advice. AEMD is a client of RedChip Companies, Inc. and of RedChip Visibility, a division of RedChip Companies. AEMD paid RedChip Visibility, a division of RedChip Companies, Inc., one hundred thousand shares of Rule 144 common stock for RedChip Visibility Program services, which includes the preparation of the equity research report(s). The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. Information contained in the equity research report(s) is obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed. RedChip Companies, Inc. is currently engaged by this company to provide investor awareness services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. These services may include investor conferences, digital and print distribution of AEMD investor-related materials, investor road shows and radio programming. AEMD agreed to pay RedChip Companies, Inc. three hundred thousand shares of Rule 144 common stock for six months of these investor relations services. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein.